Tatsuo Fuseya

Gonadotropin-Releasing Hormone Receptor in Gynecologic Tumors Frequent Expression in Adenocarcinoma Histologic Types

Background. Gonadotropin‐releasing hormone (GnRH) analogs have been used in the therapy of the endocrine‐dependent cancers. The authors attempted to determine the frequency with which Gn‐RH receptor (Gn‐RHR) is present in gynecological cancers.

Evidence for coupling of phosphotyrosine phosphatase to gonadotropin-releasing hormone receptor in ovarian carcinoma membrane

Gonadotropin‐releasing hormone (Gn‐RH) receptor (Gn‐RHR) has been demonstrated in epithelial ovarian carcinoma (Imai et al., Cancer 1994;74:2555‐61). To examine whether Gn‐RHR mediates direct antiproliferative effects, we attempted to determine stimulatory regulation by Gn‐RH of phosphotyrosine phosphatase (PTP) activity in plasma membranes isolated from ovarian carcinoma samples.

Detection of SRY in 45,X/47,XYY mosaicism leading to phenotypic female

SRY on the Y chromosome initiates male sex determination. We tested a phenotypic female with sex chromosome mosaicism, X/XYY, for SRY expression. SRY was determined by polymerase chain reaction (PCR) amplification in genomic DNA from a female patient with a sex chromosome mosaic complement, 45, X/47, XYY, followed by sequencing analyses. The patient yielded the PCR product with predicted size and homology to the consensus sequence of SRY. The demonstration of SRY provides evidence that the female phenotype in the presence of sex chromosome mosaicism, X/XYY, may result from alterations in another part of the sex‐determining pathway or downstream from SRY.

A gonadotropin-releasing hormone analogue impairs glucose tolerance in a diabetic patient.

Changes in serum glucose levels were examined in a female with insulin-independent diabetes who received a gonadotropin-releasing hormone (GnRH) analog treatment for pelvic endometriosis. The mean blood glucose levels were higher on busereline therapy, and higher levels of hemoglobin A1c were noted on busereline therapy (range 6.9-12.5%) versus pre- and post-treatment (range 5.1-5.9%). Hormonal alteration induced by GnRH analog treatment may impair glucose tolerance.